Dana-farber Cancer Institute

This study tests a new drug called IPI-145 combined with standard chemotherapy (FCR) in 32 younger adults (ages 18-65) with untreated chronic lymphocytic leukemia (CLL). The goal is to see if the combination is safe and can make the cancer disappear from the bone marrow (called M…

This study looks at whether removing just the tumor with surgery is enough for women with a very early, low-grade breast condition called DCIS. About 158 participants will have only the surgery and then be followed with regular check-ups and mammograms to see if the cancer comes …

This study tests a combination of two drugs, ibrutinib and obinutuzumab, in people with chronic lymphocytic leukemia (CLL) whose cancer has returned or not responded to prior therapy. The main goal is to check the safety of different dosing schedules. About 54 adults with CLL or …

This study tests whether combining two targeted drugs, osimertinib and selumetinib, works better than standard care for people with advanced EGFR-mutant non-small cell lung cancer. About 25 participants will receive the combination to see how many respond and how long the cancer …

This early-phase study tests a personalized vaccine made from each patient's unique tumor mutations, combined with immunotherapy (pembrolizumab), after standard rituximab treatment for follicular lymphoma. The goal is to see if this approach is feasible and can boost the immune s…

This study tests a combination of three drugs (acalabrutinib, venetoclax, and obinutuzumab) as an initial treatment for people with chronic lymphocytic leukemia (CLL) who have not had prior therapy. The goal is to see if this combination can clear leukemia cells from the bone mar…

This study tests a drug called acalabrutinib in people whose central nervous system lymphoma has returned or not responded to prior therapy. The goal is to find the safest dose and see how well it shrinks tumors. About 49 adults will take part in this early-phase trial.

This study looks at whether a 16-week exercise program can lower inflammation in fat tissue for women who have finished treatment for early-stage breast cancer. About 100 participants will take part to see if movement helps reduce markers linked to cancer recurrence. The goal is …

This study tests whether adding the targeted drug ibrutinib to standard chemotherapy (FCR) can achieve deep remission in younger adults with untreated chronic lymphocytic leukemia (CLL). About 85 participants will receive the combination and be monitored for minimal residual dise…

This study tests whether a newer drug, Margetuximab, works better than the standard drug Trastuzumab when combined with chemotherapy and another targeted therapy before surgery for stage II-III HER2-positive breast cancer. About 174 participants will receive one of the two drug c…

This study tests a new form of chemotherapy called calaspargase pegol (SC-PEG) in 240 children and teens with acute lymphoblastic leukemia or lymphoblastic lymphoma. The goal is to see if giving it every 3 weeks is as safe and effective as the standard drug Oncaspar given every 2…

This study tested the drug pembrolizumab (Keytruda) in 18 people with aggressive lymphomas or rare immune cell cancers that had come back or not responded to other treatments. The goal was to see if the drug could shrink tumors. The study is currently on hold.

This early-phase trial tests the safety of combining donor anti-inflammatory Treg cells with low-dose interleukin-2 (IL-2) for people with chronic graft-versus-host disease (cGVHD) that hasn't responded to steroids. cGVHD is a condition where the donor's immune cells attack the r…

This study tests whether combining two targeted drugs, osimertinib and gefitinib, is safe and feasible for people with advanced EGFR-mutant non-small cell lung cancer. About 48 participants who have not received prior EGFR inhibitor treatment will take both drugs for up to 6 cycl…

This early-phase study tests whether adding the drug venetoclax to standard chemotherapy is safe and tolerable for people with newly diagnosed acute myeloid leukemia (AML). About 50 adults will receive the combination during initial treatment and a follow-up consolidation phase. …

This study tests a combination of three drugs (bortezomib, lenalidomide, and dexamethasone) in people newly diagnosed with multiple myeloma, a type of blood cancer. The goal is to find the safest dose and see how well the drugs work together to control the disease. 68 adults aged…

This study tests a combination of two targeted drugs (trastuzumab and pertuzumab) plus hormone therapy given after surgery to people with early-stage, hormone receptor-positive, HER2-positive breast cancer. The goal is to see if this approach helps prevent the cancer from coming …

This study tests a CAR-T cell therapy called cilta-cel in 20 people with high-risk smoldering myeloma, a pre-cancer condition. The treatment uses a patient's own immune cells, modified to attack myeloma cells. The goal is to see if it is safe and can prevent or delay the disease …

This study tests two drugs, ipilimumab and nivolumab, given alone or together, in people with classic Hodgkin lymphoma that has returned or not responded to prior treatments. The goal is to see if these drugs can shrink or control the cancer. About 13 adults with measurable disea…

This study looks at whether different levels of exercise can help improve heart health in young adults (ages 18-39) who survived childhood cancer and were treated with a type of chemotherapy called anthracyclines. Participants will follow an exercise program, and researchers will…

This study tests a combination of two immunotherapy drugs, nivolumab and ipilimumab, in about 100 adults with rare cancers of the urinary and reproductive systems. The goal is to see if the drugs can shrink tumors and control the disease. Participants must have advanced cancer th…

This study tested the drug clofarabine in 25 people with Langerhans cell histiocytosis (LCH) or related disorders that had returned or not improved with standard therapy. The goal was to see if the drug could shrink or eliminate disease. Results measured how many patients had the…

This early-phase study tests a personalized vaccine called NeoVax, made from a person's own tumor mutations, combined with an immune booster (CDX-301) and standard immunotherapy drugs (nivolumab or pembrolizumab) for melanoma. The goal is to see if the combination is safe and can…

This early-phase trial tests a three-drug combination (ribociclib, everolimus, and dexamethasone) in children and young adults aged 1 to 30 whose acute lymphoblastic leukemia has returned or not responded to standard treatments. The main goals are to find the safest dose and unde…

This study tests whether adding the immunotherapy drug nivolumab to standard chemotherapy (carboplatin) helps people with metastatic triple-negative breast cancer live longer without their disease getting worse. About 78 participants with advanced breast cancer that has spread wi…

This study is testing whether combining two drugs, copanlisib and venetoclax, can help people with a type of blood cancer called diffuse large B-cell lymphoma that has come back or not responded to prior treatments. About 48 adults will take part. The goal is to find the safest d…

This early-phase study tests a modified herpes virus designed to attack brain tumor cells directly. The virus is injected into the tumor, and some participants also receive a drug to boost the immune response. The main goal is to find the safest dose and see how the body reacts. …

This study tests a new drug (duvelisib) combined with an approved drug (venetoclax) in 55 adults whose chronic lymphocytic leukemia (CLL) or Richter's syndrome has come back or not responded to prior treatment. The goal is to see how well the combination shrinks or controls the c…

This study tests whether two drugs, olaparib and ceralasertib, can help control osteosarcoma that has come back or not responded to treatment. About 63 people aged 12 to 40 with recurrent osteosarcoma will receive the drug combination. The goal is to see if the treatment can stop…

This study tests a combination of two drugs, olaparib and sapacitabine, in people with advanced breast cancer that has a BRCA gene mutation. The main goals are to find the safest dose and see if the drugs shrink tumors. About 10 participants will take part in this early-phase tri…

This study tests whether adding the targeted drug ruxolitinib to standard chemotherapy can improve treatment for a rare, aggressive type of breast cancer called inflammatory breast cancer (IBC). The trial enrolled 23 people with triple-negative IBC. Researchers measured how well …

This study tests whether giving two targeted drugs (T-DM1 and pertuzumab) before surgery can eliminate all signs of cancer in women with early-stage HER2-positive breast cancer. About 164 participants with stage II or III disease will receive the combination, and doctors will che…

This study tests whether a 16-week home-based, virtually supervised high-intensity interval training (HIIT) program can slow prostate cancer progression in Black men who are on active surveillance (monitoring the cancer without immediate treatment). The trial enrolls 68 Black men…

This study is for children and teens newly diagnosed with acute lymphoblastic leukemia (ALL), a cancer of the blood. The standard treatment is about 2 years of chemotherapy. This trial tests a new set of risk factors to decide how strong the treatment should be, and a new way to …

This early-phase study tests a new treatment for people whose blood cancer (like AML or MDS) has returned after a donor stem cell transplant. The treatment combines a special type of donor immune cell infusion with an immunotherapy drug (ipilimumab) to help fight the cancer. The …

This study tested a two-step drug combination (rituximab/bendamustine followed by rituximab/cytarabine) in 23 adults with newly diagnosed mantle cell lymphoma who were eligible for a stem cell transplant. The goal was to see if this approach could improve the number of patients a…

This study tests a drug called daratumumab in people with two early blood conditions that can lead to multiple myeloma. The goal is to see if the drug can reduce or control the abnormal cells, preventing progression to active cancer. Participants receive treatment for up to 20 cy…

This study looks at women with HER2-positive breast cancer who had a complete response to a three-drug combination before surgery. The goal is to see if they can safely skip chemotherapy after surgery and only receive two antibody drugs. About 100 participants are enrolled to tes…

This study tests a new imaging method to find the first lymph node that drains from a lung tumor, which is the most likely place for cancer to spread. About 57 adults with early-stage lung cancer will have this node removed during surgery for analysis. The goal is to improve dete…

This study tests whether metformin, a widely used diabetes medicine, can prevent the progression of two precancerous blood conditions (MGUS and smoldering multiple myeloma) into active multiple myeloma. About 60 participants will receive either metformin or a placebo pill for a p…

This study tested whether talking to an exercise specialist over the phone can help breast and colorectal cancer survivors become more active after finishing chemotherapy. 120 people who had completed treatment for early-stage cancer took part. The goal was to see if this approac…

This study is testing whether people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) can safely increase their dose of venetoclax faster than the usual 5-week schedule. The main goal is to see which risk groups for tumor lysis syndrome can tolerate a d…

This study tests two brief video-based programs to help young women (ages 19-49) who have had cancer and are dealing with sexual health issues. About 84 participants will join from home via videoconference. The goal is to see which program better improves sexual function and redu…

This study looks at whether a 16-week home exercise program can help Black and Hispanic patients with breast, colorectal, or prostate cancer become more active during chemotherapy. Participants are assigned to supervised exercise via Zoom, unsupervised exercise, or stretching. Th…

This study looks at 271 people with pancreatic cancer to find genetic factors that may increase risk. Researchers will collect personal and family medical history and test for inherited gene changes. The goal is to build a tool that helps doctors identify high-risk patients earli…

This study looks at whether certain inherited gene changes (EGFR mutations) increase the risk of lung cancer, especially in people who never smoked. Researchers collect saliva from cancer patients with a specific tumor mutation (T790M) to see if they carry an inherited mutation. …

This study looks at how people feel physically and emotionally after having a breast biopsy for certain non-cancerous but atypical breast conditions. Over 900 participants from several hospitals answered questions about pain and quality of life, on average nearly four years after…

This study looks at women recently diagnosed with breast cancer who take part in exercise or mind-body programs for 3-6 weeks before their surgery. Researchers want to see if these programs help reduce stress, anxiety, and improve mood and quality of life. They also check for cha…

This study looks at whether testing the genes of a child's tumor can help doctors choose a targeted therapy that might work better. It involves children and young adults up to age 30 with solid tumors that have come back or not responded to standard treatment. Researchers will tr…

This study collects bone marrow and blood samples, along with medical history, from people with multiple myeloma, Waldenstrom macroglobulinemia, and related disorders. The samples are stored in a tissue bank for researchers to study the causes and biology of these diseases. The g…

This early-phase trial is testing the immunotherapy drug pembrolizumab in 60 adults whose glioblastoma (a type of brain cancer) has come back or worsened. The main goal is to see how the drug affects immune cells inside the tumor and to check for side effects. Participants receiv…

This study looks at whether a genomic test called Prosigna can help doctors and patients choose the best treatment before breast cancer surgery. It involves 60 women with a specific type of breast cancer (HR+/Her2-). The main goal is to see if the test results change the treatmen…

This study looks at how a 12-week physical activity program affects certain markers in the breast tissue and blood of premenopausal women with dense breasts. Dense breast tissue is a risk factor for breast cancer, and the goal is to see if exercise can cause changes that might lo…

This study follows 253 breast cancer patients aged 70 and older to learn how to improve their treatment and health outcomes. Researchers will track what treatments doctors recommend, how well patients stick to hormone therapy, and what barriers they face. The goal is to find bett…

This study looks at whether whole body MRI scans can help find cancer early in children and adults with Li-Fraumeni syndrome, a genetic condition that greatly increases cancer risk. About 150 participants will get annual scans for four years to see if they keep coming back and ho…

This study follows over 1,300 women aged 40 or younger who were recently diagnosed with breast cancer. Researchers collect surveys, blood samples, and tumor tissue to learn about short- and long-term effects of the disease and its treatment, including fertility, sexual health, an…